28 research outputs found
In Vitro studies on the regulation of erythropoiesis by erythropoietin and stem cell factor
In this thesis we set out to unravel the components of the EpoR/c-Kit signalling complex to
gain insight into the intracellular proteins involved in Epo and SCF regulated differentiation,
survival and expansion. At present the proteins responsible for these processes are poorly
described though recent data indicates that PI3K dependent signal transduction drives the
expansion of erythroid progenitors. Absence of these signals results in accelerated differentiation.
The signal transducing mediators downstream of PI3K may thus be part of an important
switch, responsible for the regulation of the amounts of erythrocytes produced. Due to
their described role in signal amplification and mitogenic signalling we focussed on PI3K regulated
Tee-family kinases and docking molecules activated by SCF and/or Ep
Stem cell factor induces phosphatidylinositol 3'-kinase-dependent Lyn/Tec/Dok-1 complex formation in hematopoietic cells
Stem cell factor (SCF) has an important role in the proliferation,
differentiation, survival, and migration of hematopoietic cells. SCF
exerts its effects by binding to cKit, a receptor with intrinsic tyrosine
kinase activity. Activation of phosphatidylinositol 3'-kinase (PI3-K) by
cKit was previously shown to contribute to many SCF-induced cellular
responses. Therefore, PI3-K-dependent signaling pathways activated by SCF
were investigated. The PI3-K-dependent activation and phosphorylation of
the tyrosine kinase Tec and the adapter molecule p62Dok-1 are reported.
The study shows that Tec and Dok-1 form a stable complex with Lyn and 2
unidentified phosphoproteins of 56 and 140 kd. Both the Tec homology and
the SH2 domain of Tec were identified as being required for the
interaction with Dok-1, whereas 2 domains in Dok-1 appeared to mediate the
association with Tec. In addition, Tec and Lyn were shown to phosphorylate
Dok-1, whereas phosphorylated Dok-1 was demonstrated to bind to the SH2
domains of several signaling molecules activated by SCF, including Abl,
CrkL, SHIP, and PLCgamma-1, but not those of Vav and Shc. These findings
suggest that p62Dok-1 may function as an important scaffold molecule in
cKit-mediated signaling
Tyrosine kinase receptor RON functions downstream of the erythropoietin
Erythropoietin (EPO) is required for cell survival during differentiation
and for progenitor expansion during stress erythropoiesis. Although
signaling pathways may couple directly to docking sites on the EPO
receptor (EpoR), additional docking molecules expand the signaling
platform of the receptor. We studied the roles of the docking molecules
Grb2-associated binder-1 (Gab1) and Gab2 in EPO-induced signal
transduction and erythropoiesis. Inhibitors of phosphatidylinositide
3-kinase and Src kinases suppressed EPO-dependent phosphorylation of Gab2.
In contrast, Gab1 activation depends on recruitment and phosphorylation by
the tyrosine kinase receptor RON, with which it is constitutively
associated. RON activation induces the phosphorylation of Gab1,
mitogen-activated protein kinase (MAPK), and protein kinase B (PKB) but
not of signal transducer and activator of transcription 5 (Stat5). RON
activation was sufficient to replace EPO in progenitor expansion but not
in differentiation. In conclusion, we elucidated a novel mechanism
specifically involved in the expansion of erythroblasts involving RON as a
downstream target of the Epo
Grsf1-induced translation of the SNARE protein use1 is required for expansion of the erythroid compartment
Induction of cell proliferation requires a concomitant increase in the synthesis of glycosylated lipids and membrane proteins, which is dependent on ER-Golgi protein transport by CopII-coated vesicles. In this process, retrograde transport of ER resident proteins from the Golgi is crucial to maintain ER integrity, and allows for anterograde transport to continue. We previously showed that expression of the CopI specific SNARE protein Use1 (Unusual SNARE in the ER 1) is tightly regulated by eIF4E-dependent translation initiation of Use1 mRNA. Here we investigate the mechanism that controls Use1 mRNA translation. The 5'UTR of mouse Use1 contains a 156 nt alternatively spliced intron. The non-spliced form is the predominantly translated mRNA. The alternatively spliced sequence contains G-repeats that bind the RNA-binding protein G-rich sequence binding factor 1 (Grsf1) in RNA band shift assays. The presence of these G-repeats rendered translation of reporter constructs dependent on the Grsf1 concentration. Down regulation of either Grsf1 or Use1 abrogated expansion of erythroblasts. The 5'UTR of human Use1 lacks the splice donor site, but contains an additional upstream open reading frame in close proximity of the translation start site. Similar to mouse Use1, also the human 5'UTR contains G-repeats in front of the start codon. In conclusion, Grsf1 controls translation of the SNARE protein Use1, possibly by positioning the 40S ribosomal subunit and associated translation factors in front of the translation start site
SYMPHONY consortium:Orchestrating personalized treatment for patients with bleeding disorders
Background Treatment choices for individual patients with an inborn bleeding disorder are increasingly challenging due to increasing options and rising costs for society. We have initiated an integrated interdisciplinary national research program. Objectives The SYMPHONY consortium strives to orchestrate personalized treatment in patients with an inborn bleeding disorder, by unraveling the mechanisms behind interindividual variations of bleeding phenotype. Patients The SYMPHONY consortium will investigate patients with an inborn bleeding disorder, both diagnosed and not yet diagnosed. Results Research questions are categorized under the themes: (1) diagnosis, (2) treatment, and (3) fundamental research, and consist of work packages addressing specific domains. Importantly, collaborations between patients and talented researchers from different areas of expertise promise to augment the impact of the SYMPHONY consortium, leading to unique interactions and intellectual property. Conclusions SYMPHONY will perform research on all aspects of care, treatment individualization in patients with inborn bleeding disorders, as well as diagnostic innovations and results of molecular genetics and cellular model technology with regard to the hemostatic process. We believe that these research investments will lead to health-care innovations with long-term clinical and societal impact. This consortium has been made possible by a governmental, competitive grant from the Netherlands Organization for Scientific Research (NWO) within the framework of the NWA-ORC Call grant agreement NWA.1160.18.038
Viral insertion in Evi12 causes expression of aberrant Grp94 mRNAs containing the viral gag myristylation motif
AbstractEcotropic Virus Integration site 12 (Evi12) is a common virus insertion site (cVIS) in retrovirally induced murine models of leukemia and lymphoma, suggesting an important role for this locus in these hematopoietic disorders. Evi12 is located near the promoter of the ER chaperone protein and Hsp90 family member Grp94. Here we show that viral insertion in Evi12 results in the expression of aberrant Grp94 transcripts in Cas-Br-MuLV as well as in AKXD induced hematopoietic tumors, demonstrating that Grp94 is a common viral target gene. While most transcripts encode for truncated forms of Grp94, transcripts containing viral gag sequences were detected in the leukemia cell line NFS107. Interestingly, these fusion transcripts encode for myristylated viralâGrp94 fusion proteins that localize to the plasma membrane. Combined with recent evidence that myristylated forms of Hsp90 transform cells, our data suggest that myristylation of target genes may be an important mechanism in retrovirally mediated oncogenesis. Since retroviral insertion in Evi12 also affects the expression of a recently identified novel gene Grp94 neighboring nucleotidase (Gnn), located at the other side of Evi12, it appears that proviral insertion can lead to deregulation of two genes present in the same locus
The common viral insertion site Evi12 is located in the 5 '-noncoding region of Gnn, a novel gene with enhanced expression in two subclasses of human acute myeloid leukemia
The leukemia and lymphoma disease locus Evi12 was mapped to the noncoding region of a novel gene, Gnn (named for Grp94 neighboring nucleotidase), that is located immediately upstream of the Grp94/Tra1 gene on mouse chromosome 10. The Gnn gene is conserved in mice and humans. Expression of fusion constructs between GFP and Gnn cDNA isoforms in HEK-293 cells showed that Gnn proteins are located mainly in the cytoplasm. Immunoblotting experiments demonstrated the presence of multiple Gnn protein isoforms in most organs, with the lowest levels of expression of the protein detected in bone marrow and spleen. The Evi12-containing leukemia cell line NFS107 showed high levels of expression of a âŒ150-kDa Gnn isoform (Gnn(107)) that was not observed in control cell lines. Overexpression may be due to the viral insertion in Evi12. The Gnn(107) protein is probably encoded by a Gnn cDNA isoform that is expressed exclusively in NFS107 cells and that includes sequences of TU12B1-TY, a putative protein with homology to 5âČ-nucleotidase enzymes. Interestingly, using Affymetrix gene expression data of a cohort of 285 patients with acute myeloid leukemia (AML), we found that GNN/TU12B1-TY expression was specifically increased in two AML clusters. One cluster consisted of all AML patients with a t(8;21) translocation, and the second cluster consisted of AML patients with a normal karyotype carrying a FLT3 internal tandem duplication. These findings suggest that we identified a novel proto-oncogene that may be causally linked to certain types of human leukemia